KalVista Pharmaceuticals Inc(KALV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4 | Insider Own | 17.04% | Shs Outstand | 51.2M | Perf Week | - |
| Market Cap | 1.44B | Forward P/E | 34.18 | EPS next Y | 197.53% | Insider Trans | -3.56% | Shs Float | 44.2M | Perf Month | 0.9% |
| Enterprise Value | 1.44B | PEG | - | EPS next Q | - | Inst Own | 115.54% | Short Float | 15.49% | Perf Quarter | 74.31% |
| Income | -0.20B | P/S | 1005.23 | EPS this Y | 60.1% | Inst Trans | 2.59% | Short Ratio | 1.99 | Perf Half Y | 59.76% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -97.71% | Short Interest | 6.84M | Perf YTD | 67.18% |
| Book/sh | -0.38 | P/C | 5.04 | EPS past 3/5Y | 1.05% -5.91% | ROE | -190.18% | 52W High | 0% ($27.00) | Perf Year | 90.01% |
| Cash/sh | 5.35 | P/FCF | - | Sales past 3/5Y | - | ROIC | -82.31% | 52W Low | 174.67% ($9.83) | Perf 3Y | 172.45% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -13.14% | Gross Margin | -9.33% | Volatility(W/M) | 0.07% 0.18% | Perf 5Y | -6.57% |
| Dividend TTM | - | EV/Sales | 1004.73 | Sales Y/Y TTM | - | Oper. Margin | -14220.9% | ATR (14) | 0.23 | Perf 10Y | 70.67% |
| Dividend Ex-Date | - | Quick Ratio | 5.1 | EPS Q/Q | 59% | Profit Margin | -14242.57% | RSI (14) | 75.88 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.17 | Sales Q/Q | - | SMA20 | 0.53% ($26.86) | Beta | -0.1 | Target Price | $27 |
| Payout | - | Debt/Eq | - | Earnings | 2026/3/25 | SMA50 | 12.45% ($24.01) | Rel Volume | 0 | Prev Close | $27 |
| Employees | 275 | LT Debt/Eq | - | EPS/Sales Surpr. | 11.5% -100% | SMA200 | 60.3% ($16.84) | Avg Volume(3M) | 3.45M | Price | $27 |
| IPO | 2015/4/9 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
Company
KALV is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 KalVista Pharmaceuticals (KALV) is a biotech company that develops oral small-molecule drugs targeting protease enzymes such as plasma kallikrein. Its lead product, sebetralstat—an oral, on-demand treatment for hereditary angioedema—received U.S. FDA approval, marking its entry into the commercialization stage, and the company is pursuing expansion into additional indications.
Over the past 1 year, on the higher side
0% below its 1-year high.
KALV has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +60.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 1 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by +172.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 115.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
LFSC 0.04%
BBP 0.03%
ARB 0.02%
MRGR 0.02%
EVNT 0.02%It ranks #4 in the industry
Based on market cap of $1B.
KALV $1B PER -
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is KALV?
KALV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KALV?
The market cap of KALV is approximately $1.4B, ranking 2,369 within its sector.
What is the 52-week high and low for KALV?
KALV has recorded a 52-week high of $27.00 and a low of $9.83.
